General American Investors Company Lowered Gilead Sciences (GILD) Holding By $1.62 Million; Security Equity Account Thirteen Has 2.14 Sentiment

January 19, 2018 - By Peter Erickson

General American Investors Company Inc decreased Gilead Sciences Inc. (GILD) stake by 4.14% reported in 2017Q3 SEC filing. General American Investors Company Inc sold 20,000 shares as Gilead Sciences Inc. (GILD)’s stock declined 8.05%. The General American Investors Company Inc holds 463,600 shares with $37.56M value, down from 483,600 last quarter. Gilead Sciences Inc. now has $106.03B valuation. The stock decreased 0.70% or $0.57 during the last trading session, reaching $81.17. About 8.53 million shares traded or 1.94% up from the average. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 19, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

The stock increased 0.31% or $0.04 during the last trading session, reaching $12.78. About 12,894 shares traded. The New Ireland Fund, Inc. (IRL) has risen 0.90% since January 19, 2017 and is uptrending. It has underperformed by 15.80% the S&P500.

Shaker Financial Services Llc holds 0.65% of its portfolio in The New Ireland Fund, Inc. for 89,138 shares. Alpine Global Management Llc owns 43,953 shares or 0.17% of their US portfolio. Moreover, Bulldog Investors Llc has 0.13% invested in the company for 31,795 shares. The Virginia-based 1607 Capital Partners Llc has invested 0.11% in the stock. City Of London Investment Management Co Ltd, a United Kingdom-based fund reported 66,000 shares.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 earnings per share, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.18B for 12.15 P/E if the $1.67 EPS becomes a reality. After $2.23 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained the shares of GILD in report on Tuesday, March 15 with “Hold” rating. The rating was initiated by William Blair with “Buy” on Thursday, August 31. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Hold” rating given on Tuesday, May 30 by Maxim Group. Piper Jaffray upgraded the shares of GILD in report on Thursday, November 5 to “Overweight” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given on Wednesday, October 18 by Cowen & Co. The firm has “Mkt Perform” rating given on Tuesday, September 27 by Leerink Swann. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Hold” rating by Jefferies on Wednesday, October 4. Jefferies maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Wednesday, October 5. Jefferies has “Buy” rating and $93 target. Jefferies maintained the stock with “Buy” rating in Monday, June 12 report. UBS maintained the stock with “Buy” rating in Friday, April 29 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com